Ultrasensitive quantification of serum vitamin D metabolites using selective solid-phase extraction coupled to microflow liquid chromatography and isotope-dilution mass spectrometry

The capacity for quantification of active metabolites of vitamin D (VitD) is highly valuable to evaluate the risks and therapies for numerous diseases such as multiple sclerosis. However, the extremely low circulating levels and poor detectability of some dihydroxyl metabolites such as the 1alpha,25...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Analytical chemistry (Washington) Ročník 82; číslo 6; s. 2488
Hlavní autori: Duan, Xiaotao, Weinstock-Guttman, Bianca, Wang, Hao, Bang, Eunjin, Li, Jun, Ramanathan, Murali, Qu, Jun
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 15.03.2010
Predmet:
ISSN:1520-6882, 1520-6882
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract The capacity for quantification of active metabolites of vitamin D (VitD) is highly valuable to evaluate the risks and therapies for numerous diseases such as multiple sclerosis. However, the extremely low circulating levels and poor detectability of some dihydroxyl metabolites such as the 1alpha,25-dihydroxy-VitD(3) constitute a daunting challenge. Based on the combination of a selective solid-phase extraction (SPE) and a microflow liquid chromatography tandem mass spectrometry (microLC-MS/MS), we developed an ultrasensitive method for the robust, selective, and accurate quantification of four key VitD metabolites, including 25-hydroxy-VitD(2), 25-hydroxy-VitD(3), 24(R),25-dihydroxy-VitD(3), and 1alpha,25-dihydroxy-VitD(3), in serum samples. A one-step derivatization was employed to improve the ionization efficiency of the metabolites. The SPE procedure was optimized so that the analytes were selectively extracted from serum, while the sample matrix was substantially simplified. By eliminating majority of undesirable compounds from the matrix, the selective SPE enabled a high sample loading volume on the microLC column without causing overcapacity of the microLC column and thus helped to achieve ultralow detect limits in serum. An on-column sample focusing approach was employed to prevent band-broadening, and a sufficient microLC separation was achieved to eliminate endogenous interferences and to minimize ion suppression effect. Detect limits of the four metabolites ranged from 0.5-1 pg/mL, and the linearity was excellent for all compounds. The method showed high quantitative accuracy (error < 13.8%) and precision (CV < 14.1%). For 1alpha,25-dihydroxy-VitD(3), a lower limit of quantification (LLOQ) of 5 pg/mL was validated. This high level of sensitivity, for the first time, enabled the robust and consistent LC/MS/MS-based analysis of the four metabolites in a large-scale clinical investigation. Serum samples from 281 multiple sclerosis patients and 22 healthy subjects were analyzed, and it was discovered that the levels of both 24(R),25-dihydroxy-VitD(3) and 1alpha,25-dihydroxy-VitD(3) were significantly lower in patients than healthy subjects (P < 0.05). This novel observation may imply that the incidence of multiple sclerosis is inversely associated with the levels of the two metabolites. Moreover, the method was highly robust and reproducible as evaluated extensively in the clinical analysis; therefore, it could serve as a more selective and accurate alternative to immunoassay for large-scale clinical studies.
AbstractList The capacity for quantification of active metabolites of vitamin D (VitD) is highly valuable to evaluate the risks and therapies for numerous diseases such as multiple sclerosis. However, the extremely low circulating levels and poor detectability of some dihydroxyl metabolites such as the 1alpha,25-dihydroxy-VitD(3) constitute a daunting challenge. Based on the combination of a selective solid-phase extraction (SPE) and a microflow liquid chromatography tandem mass spectrometry (microLC-MS/MS), we developed an ultrasensitive method for the robust, selective, and accurate quantification of four key VitD metabolites, including 25-hydroxy-VitD(2), 25-hydroxy-VitD(3), 24(R),25-dihydroxy-VitD(3), and 1alpha,25-dihydroxy-VitD(3), in serum samples. A one-step derivatization was employed to improve the ionization efficiency of the metabolites. The SPE procedure was optimized so that the analytes were selectively extracted from serum, while the sample matrix was substantially simplified. By eliminating majority of undesirable compounds from the matrix, the selective SPE enabled a high sample loading volume on the microLC column without causing overcapacity of the microLC column and thus helped to achieve ultralow detect limits in serum. An on-column sample focusing approach was employed to prevent band-broadening, and a sufficient microLC separation was achieved to eliminate endogenous interferences and to minimize ion suppression effect. Detect limits of the four metabolites ranged from 0.5-1 pg/mL, and the linearity was excellent for all compounds. The method showed high quantitative accuracy (error < 13.8%) and precision (CV < 14.1%). For 1alpha,25-dihydroxy-VitD(3), a lower limit of quantification (LLOQ) of 5 pg/mL was validated. This high level of sensitivity, for the first time, enabled the robust and consistent LC/MS/MS-based analysis of the four metabolites in a large-scale clinical investigation. Serum samples from 281 multiple sclerosis patients and 22 healthy subjects were analyzed, and it was discovered that the levels of both 24(R),25-dihydroxy-VitD(3) and 1alpha,25-dihydroxy-VitD(3) were significantly lower in patients than healthy subjects (P < 0.05). This novel observation may imply that the incidence of multiple sclerosis is inversely associated with the levels of the two metabolites. Moreover, the method was highly robust and reproducible as evaluated extensively in the clinical analysis; therefore, it could serve as a more selective and accurate alternative to immunoassay for large-scale clinical studies.
The capacity for quantification of active metabolites of vitamin D (VitD) is highly valuable to evaluate the risks and therapies for numerous diseases such as multiple sclerosis. However, the extremely low circulating levels and poor detectability of some dihydroxyl metabolites such as the 1alpha,25-dihydroxy-VitD(3) constitute a daunting challenge. Based on the combination of a selective solid-phase extraction (SPE) and a microflow liquid chromatography tandem mass spectrometry (microLC-MS/MS), we developed an ultrasensitive method for the robust, selective, and accurate quantification of four key VitD metabolites, including 25-hydroxy-VitD(2), 25-hydroxy-VitD(3), 24(R),25-dihydroxy-VitD(3), and 1alpha,25-dihydroxy-VitD(3), in serum samples. A one-step derivatization was employed to improve the ionization efficiency of the metabolites. The SPE procedure was optimized so that the analytes were selectively extracted from serum, while the sample matrix was substantially simplified. By eliminating majority of undesirable compounds from the matrix, the selective SPE enabled a high sample loading volume on the microLC column without causing overcapacity of the microLC column and thus helped to achieve ultralow detect limits in serum. An on-column sample focusing approach was employed to prevent band-broadening, and a sufficient microLC separation was achieved to eliminate endogenous interferences and to minimize ion suppression effect. Detect limits of the four metabolites ranged from 0.5-1 pg/mL, and the linearity was excellent for all compounds. The method showed high quantitative accuracy (error < 13.8%) and precision (CV < 14.1%). For 1alpha,25-dihydroxy-VitD(3), a lower limit of quantification (LLOQ) of 5 pg/mL was validated. This high level of sensitivity, for the first time, enabled the robust and consistent LC/MS/MS-based analysis of the four metabolites in a large-scale clinical investigation. Serum samples from 281 multiple sclerosis patients and 22 healthy subjects were analyzed, and it was discovered that the levels of both 24(R),25-dihydroxy-VitD(3) and 1alpha,25-dihydroxy-VitD(3) were significantly lower in patients than healthy subjects (P < 0.05). This novel observation may imply that the incidence of multiple sclerosis is inversely associated with the levels of the two metabolites. Moreover, the method was highly robust and reproducible as evaluated extensively in the clinical analysis; therefore, it could serve as a more selective and accurate alternative to immunoassay for large-scale clinical studies.The capacity for quantification of active metabolites of vitamin D (VitD) is highly valuable to evaluate the risks and therapies for numerous diseases such as multiple sclerosis. However, the extremely low circulating levels and poor detectability of some dihydroxyl metabolites such as the 1alpha,25-dihydroxy-VitD(3) constitute a daunting challenge. Based on the combination of a selective solid-phase extraction (SPE) and a microflow liquid chromatography tandem mass spectrometry (microLC-MS/MS), we developed an ultrasensitive method for the robust, selective, and accurate quantification of four key VitD metabolites, including 25-hydroxy-VitD(2), 25-hydroxy-VitD(3), 24(R),25-dihydroxy-VitD(3), and 1alpha,25-dihydroxy-VitD(3), in serum samples. A one-step derivatization was employed to improve the ionization efficiency of the metabolites. The SPE procedure was optimized so that the analytes were selectively extracted from serum, while the sample matrix was substantially simplified. By eliminating majority of undesirable compounds from the matrix, the selective SPE enabled a high sample loading volume on the microLC column without causing overcapacity of the microLC column and thus helped to achieve ultralow detect limits in serum. An on-column sample focusing approach was employed to prevent band-broadening, and a sufficient microLC separation was achieved to eliminate endogenous interferences and to minimize ion suppression effect. Detect limits of the four metabolites ranged from 0.5-1 pg/mL, and the linearity was excellent for all compounds. The method showed high quantitative accuracy (error < 13.8%) and precision (CV < 14.1%). For 1alpha,25-dihydroxy-VitD(3), a lower limit of quantification (LLOQ) of 5 pg/mL was validated. This high level of sensitivity, for the first time, enabled the robust and consistent LC/MS/MS-based analysis of the four metabolites in a large-scale clinical investigation. Serum samples from 281 multiple sclerosis patients and 22 healthy subjects were analyzed, and it was discovered that the levels of both 24(R),25-dihydroxy-VitD(3) and 1alpha,25-dihydroxy-VitD(3) were significantly lower in patients than healthy subjects (P < 0.05). This novel observation may imply that the incidence of multiple sclerosis is inversely associated with the levels of the two metabolites. Moreover, the method was highly robust and reproducible as evaluated extensively in the clinical analysis; therefore, it could serve as a more selective and accurate alternative to immunoassay for large-scale clinical studies.
Author Li, Jun
Qu, Jun
Bang, Eunjin
Duan, Xiaotao
Weinstock-Guttman, Bianca
Ramanathan, Murali
Wang, Hao
Author_xml – sequence: 1
  givenname: Xiaotao
  surname: Duan
  fullname: Duan, Xiaotao
  organization: Department of Pharmaceutical Sciences, University at Buffalo, State University of New York, Amherst, New York 14260-1200, USA
– sequence: 2
  givenname: Bianca
  surname: Weinstock-Guttman
  fullname: Weinstock-Guttman, Bianca
– sequence: 3
  givenname: Hao
  surname: Wang
  fullname: Wang, Hao
– sequence: 4
  givenname: Eunjin
  surname: Bang
  fullname: Bang, Eunjin
– sequence: 5
  givenname: Jun
  surname: Li
  fullname: Li, Jun
– sequence: 6
  givenname: Murali
  surname: Ramanathan
  fullname: Ramanathan, Murali
– sequence: 7
  givenname: Jun
  surname: Qu
  fullname: Qu, Jun
BackLink https://www.ncbi.nlm.nih.gov/pubmed/20151683$$D View this record in MEDLINE/PubMed
BookMark eNpNkMtOHDEQRa2IKDySBT-AvGPV4Efb015GQEIkJDZhPapxVzOO_Ojxg2Q-LP-X1gQkVlUqnXtKuqfkKKaIhJxzdsWZ4NdgDRODNvsP5IQrwTo9DOLo3X5MTkv5xRjnjOtP5Fgwrrge5An5--RrhoKxuOpekO4axOomZ6G6FGmaaMHcAn1xFYKL9JYGrLBJ3lUstBUXnxfCoz2ky3Ifu3m7CCn-WcT2YLGpzR5HWhMNzuY0-fSberdrbqR2m1OAmp4zzNs9hThSV1JNM3aj8-2QD1AKLfPyZGGx5v1n8nECX_DL6zwjT9_uft7cdw-P33_cfH3ooJer2knZm2kyo9KD6KdhJZnuN5M2AyowkgvgWgBToJCjASWsldoIqZFverWA4oxc_vfOOe0alroOrlj0HiKmVtYrKfmgpDILefFKtk3AcT1nFyDv129Ni3_Eooc2
CitedBy_id crossref_primary_10_1016_j_talanta_2020_121692
crossref_primary_10_4155_bio_11_195
crossref_primary_10_1007_s11154_013_9241_0
crossref_primary_10_1002_mas_21408
crossref_primary_10_1038_srep21080
crossref_primary_10_1016_j_chroma_2011_02_004
crossref_primary_10_1038_ncomms9468
crossref_primary_10_4155_bio_2020_0038
crossref_primary_10_1016_j_jchromb_2016_04_034
crossref_primary_10_1210_jc_2012_2790
crossref_primary_10_1002_jssc_201000410
crossref_primary_10_1016_j_jpba_2016_06_024
crossref_primary_10_1007_s42000_020_00188_9
crossref_primary_10_1007_s00223_012_9693_3
crossref_primary_10_1515_cclm_2021_0441
crossref_primary_10_1016_j_trac_2018_11_008
crossref_primary_10_1016_j_clinbiochem_2012_06_030
crossref_primary_10_4155_bio_14_36
crossref_primary_10_1016_j_jchromb_2013_05_029
crossref_primary_10_1016_j_trac_2016_02_005
crossref_primary_10_1016_j_chroma_2021_462444
crossref_primary_10_4155_bio_13_283
crossref_primary_10_1002_rcm_4988
crossref_primary_10_1016_j_chroma_2021_462047
crossref_primary_10_1194_jlr_D073536
crossref_primary_10_1002_pmic_201200132
crossref_primary_10_1080_10408347_2023_2261130
crossref_primary_10_1136_jnnp_2012_304740
crossref_primary_10_1080_10408347_2024_2316237
crossref_primary_10_1373_clinchem_2015_241430
crossref_primary_10_1016_j_jchromb_2011_02_008
crossref_primary_10_3390_nu11112774
crossref_primary_10_1136_jnnp_2012_304661
crossref_primary_10_4155_bio_2020_0069
crossref_primary_10_1007_s13361_017_1775_z
crossref_primary_10_1016_j_jsbmb_2014_06_007
crossref_primary_10_1371_journal_pone_0123771
crossref_primary_10_4155_bio_15_183
crossref_primary_10_4155_bio_15_260
crossref_primary_10_1016_j_aca_2015_08_017
crossref_primary_10_1016_j_biortech_2024_131078
crossref_primary_10_1007_s00216_010_3993_0
crossref_primary_10_1016_j_cca_2011_05_010
crossref_primary_10_1016_j_jchromb_2011_12_021
crossref_primary_10_1002_rcm_6708
crossref_primary_10_1016_j_chroma_2012_06_007
crossref_primary_10_4155_bio_11_298
crossref_primary_10_1002_jssc_201000911
crossref_primary_10_1016_j_jns_2011_07_024
crossref_primary_10_1016_j_clinms_2017_08_005
crossref_primary_10_1016_j_jsbmb_2023_106367
crossref_primary_10_1016_j_cca_2017_08_033
crossref_primary_10_1038_s41598_024_55939_0
crossref_primary_10_7759_cureus_92683
crossref_primary_10_4155_bio_13_300
crossref_primary_10_1016_j_chroma_2014_12_084
crossref_primary_10_1016_j_jsbmb_2018_09_003
crossref_primary_10_1002_bmc_3633
crossref_primary_10_1002_jms_1657
crossref_primary_10_1007_s12268_021_1649_6
crossref_primary_10_1371_journal_pone_0053996
crossref_primary_10_1016_j_clinbiochem_2012_03_016
crossref_primary_10_1016_j_ab_2011_06_043
crossref_primary_10_1016_j_beem_2013_06_001
crossref_primary_10_1373_clinchem_2010_161174
crossref_primary_10_1515_cclm_2016_0264
crossref_primary_10_3390_nu10040482
crossref_primary_10_3390_nu13072293
crossref_primary_10_1016_j_jsbmb_2015_10_003
crossref_primary_10_1155_2015_296531
crossref_primary_10_1080_10408363_2023_2212765
crossref_primary_10_1002_mas_21353
crossref_primary_10_3109_00365513_2014_900694
crossref_primary_10_1016_j_jchromb_2024_124088
crossref_primary_10_1016_j_chroma_2011_03_051
crossref_primary_10_1080_10408363_2022_2070595
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1021/ac902869y
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Engineering
Chemistry
EISSN 1520-6882
ExternalDocumentID 20151683
Genre Validation Studies
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NIDA NIH HHS
  grantid: 1R21DA027528
GroupedDBID ---
-DZ
-~X
.DC
.K2
23M
3O-
4.4
53G
55A
5GY
5RE
5VS
6J9
7~N
85S
AABXI
AAHBH
ABBLG
ABHFT
ABHMW
ABJNI
ABLBI
ABMVS
ABOCM
ABPPZ
ABQRX
ABUCX
ACBEA
ACGFO
ACGFS
ACGOD
ACIWK
ACJ
ACKOT
ACNCT
ACPRK
ACS
ADHLV
AEESW
AENEX
AETEA
AFEFF
AFRAH
AGXLV
AHGAQ
ALMA_UNASSIGNED_HOLDINGS
AQSVZ
BAANH
BKOMP
CGR
CS3
CUPRZ
CUY
CVF
D0L
EBS
ECM
ED~
EIF
EJD
F5P
GGK
GNL
IH9
IHE
JG~
KZ1
LG6
LMP
NPM
P2P
PQQKQ
ROL
RXW
TAE
TN5
UHB
UI2
UKR
VF5
VG9
W1F
WH7
X6Y
XSW
YZZ
ZCA
~02
7X8
ID FETCH-LOGICAL-a437t-3349ff9d56824f873064bf698e5a9312a162a05a5e1e9a52cc369236e1b45bf62
IEDL.DBID 7X8
ISICitedReferencesCount 91
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000275379300045&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1520-6882
IngestDate Fri Jul 11 16:24:31 EDT 2025
Mon Jul 21 05:59:11 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a437t-3349ff9d56824f873064bf698e5a9312a162a05a5e1e9a52cc369236e1b45bf62
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
PMID 20151683
PQID 733185359
PQPubID 23479
ParticipantIDs proquest_miscellaneous_733185359
pubmed_primary_20151683
PublicationCentury 2000
PublicationDate 2010-03-15
PublicationDateYYYYMMDD 2010-03-15
PublicationDate_xml – month: 03
  year: 2010
  text: 2010-03-15
  day: 15
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Analytical chemistry (Washington)
PublicationTitleAlternate Anal Chem
PublicationYear 2010
SSID ssj0011016
Score 2.3092337
Snippet The capacity for quantification of active metabolites of vitamin D (VitD) is highly valuable to evaluate the risks and therapies for numerous diseases such as...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 2488
SubjectTerms Adult
Chromatography, Liquid - methods
Female
Humans
Limit of Detection
Male
Mass Spectrometry - methods
Middle Aged
Solid Phase Extraction - methods
Vitamin D - blood
Vitamin D - metabolism
Title Ultrasensitive quantification of serum vitamin D metabolites using selective solid-phase extraction coupled to microflow liquid chromatography and isotope-dilution mass spectrometry
URI https://www.ncbi.nlm.nih.gov/pubmed/20151683
https://www.proquest.com/docview/733185359
Volume 82
WOSCitedRecordID wos000275379300045&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Nb9QwELWgRQIOBUqBlg_NgavVOo6d-FShQsUBVj1QaW8rO7ZppE2c3SRF_DD-H2MnC1wQBy45xVaSeZ55E4_fEPIWg7Q1PHNUelxNuRE5NU5W1HlMnhEvwrtk6U_FYlEul-pqrs3p57LKnU9MjtqGKv4jP429BTG0CHXebWhsGhU3V-cOGnfJPkcmE9dlsfy9iRAT0ySXGjMkZJI7YaGMneoqqpZI9f3vxDIFmMtH__loj8nBzCzh3QSFJ-SOaw_J_YtdQ7dD8vAP7cGn5Mf1ethiCGv7VD0Em1FPdUPJVBA8IDjHBm7rQTd1C--hcQMiJp5Z7iGWy3-FPjXRiaMRwbWl3Q1OCOjut9NxCajC2K2dhSFAEyv__Dp8g3W9GWsL1c02IF2eJbNBtxbqPgyhc9TW03qABqk9pMOgUVUB3-KIXF9--HLxkc49HKjOeTFQznPlvbJCllnuyyImPMZLVTqhFWeZZjLTZ0ILx5zSIqsqLpFzSsdMLvDG7BnZa0PrXhBQyNQYQsgopH2ssLqszJksjWFW2tyoYwI786zwy8aND926MParXwY6Js8nE6-6SctjhfxHMFnyk38PfkkeTKUDnDLxiux79A_uNblX3Q51v32TsIfXxdXnn8Ij6rY
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Ultrasensitive+quantification+of+serum+vitamin+D+metabolites+using+selective+solid-phase+extraction+coupled+to+microflow+liquid+chromatography+and+isotope-dilution+mass+spectrometry&rft.jtitle=Analytical+chemistry+%28Washington%29&rft.au=Duan%2C+Xiaotao&rft.au=Weinstock-Guttman%2C+Bianca&rft.au=Wang%2C+Hao&rft.au=Bang%2C+Eunjin&rft.date=2010-03-15&rft.eissn=1520-6882&rft.volume=82&rft.issue=6&rft.spage=2488&rft_id=info:doi/10.1021%2Fac902869y&rft_id=info%3Apmid%2F20151683&rft_id=info%3Apmid%2F20151683&rft.externalDocID=20151683
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1520-6882&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1520-6882&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1520-6882&client=summon